JP2016504362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504362A5 JP2016504362A5 JP2015550675A JP2015550675A JP2016504362A5 JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5 JP 2015550675 A JP2015550675 A JP 2015550675A JP 2015550675 A JP2015550675 A JP 2015550675A JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- albumin
- composition according
- item
- substantially free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 65
- 102000009027 Albumins Human genes 0.000 claims description 34
- 108010088751 Albumins Proteins 0.000 claims description 34
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747123P | 2012-12-28 | 2012-12-28 | |
| US61/747,123 | 2012-12-28 | ||
| US13/794,705 US20140186447A1 (en) | 2012-12-28 | 2013-03-11 | Nanoparticle compositions of albumin and paclitaxel |
| US13/794,705 | 2013-03-11 | ||
| PCT/US2013/076630 WO2014105644A1 (en) | 2012-12-28 | 2013-12-19 | Nanoparticle compositions of albumin and paclitaxel |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030637A Division JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504362A JP2016504362A (ja) | 2016-02-12 |
| JP2016504362A5 true JP2016504362A5 (enExample) | 2017-02-02 |
Family
ID=51017455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550675A Pending JP2016504362A (ja) | 2012-12-28 | 2013-12-19 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
| JP2018030637A Pending JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018030637A Pending JP2018087241A (ja) | 2012-12-28 | 2018-02-23 | アルブミンおよびパクリタキセルのナノ粒子組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140186447A1 (enExample) |
| EP (1) | EP2938340A4 (enExample) |
| JP (2) | JP2016504362A (enExample) |
| KR (1) | KR20150100903A (enExample) |
| CN (1) | CN105007912A (enExample) |
| AU (1) | AU2013370955B2 (enExample) |
| BR (1) | BR112015015319A2 (enExample) |
| CA (1) | CA2896288A1 (enExample) |
| CR (1) | CR20150386A (enExample) |
| HK (1) | HK1216611A1 (enExample) |
| IL (1) | IL239593A0 (enExample) |
| MX (1) | MX2015008361A (enExample) |
| NI (1) | NI201500090A (enExample) |
| NZ (1) | NZ630912A (enExample) |
| PH (1) | PH12015501486B1 (enExample) |
| RU (1) | RU2663687C2 (enExample) |
| SG (1) | SG11201505111TA (enExample) |
| WO (1) | WO2014105644A1 (enExample) |
| ZA (1) | ZA201504762B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2880727C (en) | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| PL2552438T3 (pl) | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| JP6257324B2 (ja) | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| ES2792062T3 (es) | 2011-05-09 | 2020-11-06 | Mayo Found Medical Education & Res | Tratamientos contra el cáncer |
| SMT201900502T1 (it) | 2011-12-14 | 2019-11-13 | Abraxis Bioscience Llc | Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle |
| ES2899643T3 (es) | 2012-10-01 | 2022-03-14 | Mayo Found Medical Education & Res | Tratamientos para el cáncer |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| UA116380C2 (uk) | 2013-05-30 | 2018-03-12 | Нанобіотікс | Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| CN104224750A (zh) * | 2014-09-17 | 2014-12-24 | 四川大学 | 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| FI3229776T3 (fi) | 2014-11-25 | 2023-08-15 | Curadigm Sas | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt |
| DK3236934T3 (da) | 2014-11-25 | 2024-08-19 | Curadigm Sas | Farmaceutisk sammensætning, fremstilling og anvendelser deraf |
| ES2890662T3 (es) | 2014-11-25 | 2022-01-21 | Curadigm Sas | Composiciones farmacéuticas, preparación y usos de las mismas |
| US20170258937A1 (en) * | 2014-11-25 | 2017-09-14 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| HK1246160A1 (zh) | 2015-05-28 | 2018-09-07 | Nanobiotix | 用作治疗性疫苗的纳米粒子 |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス， エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| US11351254B2 (en) * | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| CA3035378A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| AU2017324335A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN106420665B (zh) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法 |
| JP7792750B2 (ja) | 2017-10-03 | 2025-12-26 | クリティテック・インコーポレイテッド | 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達 |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| WO2021086946A1 (en) * | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CA3161105A1 (en) * | 2019-11-11 | 2021-05-20 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| WO2021158937A1 (en) * | 2020-02-05 | 2021-08-12 | The Johns Hopkins University | Bortezomib-loaded nanoparticles |
| US20240148918A1 (en) * | 2021-03-05 | 2024-05-09 | Board Of Regents, The University Of Texas System | Loading of Alginate Microspheres |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| WO2000006152A1 (en) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| CN102573832B (zh) * | 2009-08-25 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗 |
| PL2552438T3 (pl) * | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| WO2012092712A1 (zh) * | 2011-01-07 | 2012-07-12 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂 |
| CN102078306A (zh) * | 2011-01-11 | 2011-06-01 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂 |
-
2013
- 2013-03-11 US US13/794,705 patent/US20140186447A1/en not_active Abandoned
- 2013-12-19 BR BR112015015319A patent/BR112015015319A2/pt not_active Application Discontinuation
- 2013-12-19 JP JP2015550675A patent/JP2016504362A/ja active Pending
- 2013-12-19 RU RU2015131141A patent/RU2663687C2/ru active
- 2013-12-19 KR KR1020157020337A patent/KR20150100903A/ko not_active Withdrawn
- 2013-12-19 MX MX2015008361A patent/MX2015008361A/es unknown
- 2013-12-19 AU AU2013370955A patent/AU2013370955B2/en active Active
- 2013-12-19 SG SG11201505111TA patent/SG11201505111TA/en unknown
- 2013-12-19 CA CA2896288A patent/CA2896288A1/en not_active Abandoned
- 2013-12-19 NZ NZ630912A patent/NZ630912A/en unknown
- 2013-12-19 CN CN201380073926.7A patent/CN105007912A/zh active Pending
- 2013-12-19 HK HK16104504.3A patent/HK1216611A1/zh unknown
- 2013-12-19 EP EP13868481.6A patent/EP2938340A4/en not_active Withdrawn
- 2013-12-19 WO PCT/US2013/076630 patent/WO2014105644A1/en not_active Ceased
-
2015
- 2015-06-23 IL IL239593A patent/IL239593A0/en unknown
- 2015-06-26 PH PH12015501486A patent/PH12015501486B1/en unknown
- 2015-06-26 NI NI201500090A patent/NI201500090A/es unknown
- 2015-07-02 ZA ZA2015/04762A patent/ZA201504762B/en unknown
- 2015-07-22 CR CR20150386A patent/CR20150386A/es unknown
-
2018
- 2018-02-23 JP JP2018030637A patent/JP2018087241A/ja active Pending
- 2018-10-25 US US16/170,522 patent/US20190192477A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504362A5 (enExample) | ||
| RU2015131141A (ru) | Композиции наночастиц альбумина и паклитаксела | |
| AT515178A5 (de) | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie | |
| JP2016513075A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| JP2016512513A5 (enExample) | ||
| Thomas et al. | Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| AR095456A1 (es) | Composiciones de dos componentes que contienen complejos de halogenuro de cinc y aminoácido y cisteína | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| WO2015018380A3 (en) | Therapeutic nanoparticles and the preparation methods thereof | |
| JP2017517556A5 (enExample) | ||
| BR112019007087A2 (pt) | formulações de nanopartículas e métodos de fabricação e de utilização das mesmas | |
| MX2016000019A (es) | (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias. | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| WO2017017063A3 (en) | Nanoparticle-based liver-targeting therapy and imaging | |
| EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
| JP2016510326A5 (enExample) | ||
| JP2014505702A5 (enExample) | ||
| PE20091265A1 (es) | Nanoparticulas que contienen pioglitazona | |
| JP2018524306A5 (enExample) | ||
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment |